Sepsis occurs when chemicals released in the bloodstream as a result of an infection trigger production of endotoxins causing inflammation throughout the body. This causes a systemic inflammatory cascade of changes that damage multiple organ systems, leading them to fail, and often results in death.
Researchers at Rogosin have developed a lipid emulsion as a new therapy that augments the natural ability to circulate lipoproteins to neutralize and clear toxins from gram-negative bacteria from the bloodstream. These toxins are responsible for causing sepsis. Benefits of the emulsion over other approaches include (1) broad effectiveness against microbial toxins unlike antibody therapies which are very specific, (2) the emulsion amplifies a natural defense against microbial toxins, unlike receptor blockers or antibody therapies that disable normal functions, and (3) a three-day continuous intravenous infusion of the emulsion provides sustained protection across the critical early hours of septic shock. A Phase II/III clinical trial is currently being designed and is expected to begin in 6 months.